Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?

<p>Abstract</p> <p>Background</p> <p>Renal cell carcinoma (RCC) is the most common renal neoplasm. Cancer tissue is often characterized by altered energy regulation. Fatty acid-binding proteins (FABP) are involved in the intracellular transport of fatty acids (FA). We e...

Full description

Bibliographic Details
Main Authors: Moch Holger, Miller Kurt, Johannsen Manfred, Lein Michael, Jung Monika, Tölle Angelika, Jung Klaus, Kristiansen Glen
Format: Article
Language:English
Published: BMC 2009-07-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/9/248
id doaj-fbd2b6111aac465b8960b7193fb27440
record_format Article
spelling doaj-fbd2b6111aac465b8960b7193fb274402020-11-25T02:09:28ZengBMCBMC Cancer1471-24072009-07-019124810.1186/1471-2407-9-248Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?Moch HolgerMiller KurtJohannsen ManfredLein MichaelJung MonikaTölle AngelikaJung KlausKristiansen Glen<p>Abstract</p> <p>Background</p> <p>Renal cell carcinoma (RCC) is the most common renal neoplasm. Cancer tissue is often characterized by altered energy regulation. Fatty acid-binding proteins (FABP) are involved in the intracellular transport of fatty acids (FA). We examined the level of brain-type (B) and liver-type (L) FABP mRNA and the protein expression profiles of both FABPs in renal cell carcinoma.</p> <p>Methods</p> <p>Paired tissue samples of cancerous and noncancerous kidney parts were investigated. Quantitative RT-PCR, immunohistochemistry and western blotting were used to determine B- and L-FABP in tumor and normal tissues. The tissue microarray (TMA) contained 272 clinico-pathologically characterized renal cell carcinomas of the clear cell, papillary and chromophobe subtype. SPSS 17.0 was used to apply crosstables (χ<sup>2</sup>-test), correlations and survival analyses.</p> <p>Results</p> <p>B-FABP mRNA was significantly up-regulated in renal cell carcinoma. In normal tissue B-FABP mRNA was very low or often not detectable. RCC with a high tumor grading (G3 + G4) showed significantly lower B-FABP mRNA compared with those with a low grading (G1 + G2). Western blotting analysis detected B-FABP in 78% of the cases with a very strong band but in the corresponding normal tissue it was weak or not detectable. L-FABP showed an inverse relationship for mRNA quantification and western blotting. A strong B-FABP staining was present in 52% of the tumor tissues contained in the TMA. In normal renal tissue, L-FABP showed a moderate to strong immunoreactivity in proximal tubuli. L-FABP was expressed at lower rates compared with the normal tissues in 30.5% of all tumors. There was no correlation between patient survival times and the staining intensity of both FABPs.</p> <p>Conclusion</p> <p>While B-FABP is over expressed in renal cell carcinoma in comparison to normal renal tissues L-FABP appears to be reduced in tumor tissue. Although the expression behavior was not related to the survival outcome of the RCC patients, it can be assumed that these changes indicate fundamental alterations in the fatty metabolism in the RCC carcinogenesis. Further studies should identify the role of both FABPs in carcinogenesis, progression and with regard to a potential target in RCC.</p> http://www.biomedcentral.com/1471-2407/9/248
collection DOAJ
language English
format Article
sources DOAJ
author Moch Holger
Miller Kurt
Johannsen Manfred
Lein Michael
Jung Monika
Tölle Angelika
Jung Klaus
Kristiansen Glen
spellingShingle Moch Holger
Miller Kurt
Johannsen Manfred
Lein Michael
Jung Monika
Tölle Angelika
Jung Klaus
Kristiansen Glen
Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?
BMC Cancer
author_facet Moch Holger
Miller Kurt
Johannsen Manfred
Lein Michael
Jung Monika
Tölle Angelika
Jung Klaus
Kristiansen Glen
author_sort Moch Holger
title Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?
title_short Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?
title_full Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?
title_fullStr Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?
title_full_unstemmed Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?
title_sort brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?
publisher BMC
series BMC Cancer
issn 1471-2407
publishDate 2009-07-01
description <p>Abstract</p> <p>Background</p> <p>Renal cell carcinoma (RCC) is the most common renal neoplasm. Cancer tissue is often characterized by altered energy regulation. Fatty acid-binding proteins (FABP) are involved in the intracellular transport of fatty acids (FA). We examined the level of brain-type (B) and liver-type (L) FABP mRNA and the protein expression profiles of both FABPs in renal cell carcinoma.</p> <p>Methods</p> <p>Paired tissue samples of cancerous and noncancerous kidney parts were investigated. Quantitative RT-PCR, immunohistochemistry and western blotting were used to determine B- and L-FABP in tumor and normal tissues. The tissue microarray (TMA) contained 272 clinico-pathologically characterized renal cell carcinomas of the clear cell, papillary and chromophobe subtype. SPSS 17.0 was used to apply crosstables (χ<sup>2</sup>-test), correlations and survival analyses.</p> <p>Results</p> <p>B-FABP mRNA was significantly up-regulated in renal cell carcinoma. In normal tissue B-FABP mRNA was very low or often not detectable. RCC with a high tumor grading (G3 + G4) showed significantly lower B-FABP mRNA compared with those with a low grading (G1 + G2). Western blotting analysis detected B-FABP in 78% of the cases with a very strong band but in the corresponding normal tissue it was weak or not detectable. L-FABP showed an inverse relationship for mRNA quantification and western blotting. A strong B-FABP staining was present in 52% of the tumor tissues contained in the TMA. In normal renal tissue, L-FABP showed a moderate to strong immunoreactivity in proximal tubuli. L-FABP was expressed at lower rates compared with the normal tissues in 30.5% of all tumors. There was no correlation between patient survival times and the staining intensity of both FABPs.</p> <p>Conclusion</p> <p>While B-FABP is over expressed in renal cell carcinoma in comparison to normal renal tissues L-FABP appears to be reduced in tumor tissue. Although the expression behavior was not related to the survival outcome of the RCC patients, it can be assumed that these changes indicate fundamental alterations in the fatty metabolism in the RCC carcinogenesis. Further studies should identify the role of both FABPs in carcinogenesis, progression and with regard to a potential target in RCC.</p>
url http://www.biomedcentral.com/1471-2407/9/248
work_keys_str_mv AT mochholger braintypeandlivertypefattyacidbindingproteinsnewtumormarkersforrenalcancer
AT millerkurt braintypeandlivertypefattyacidbindingproteinsnewtumormarkersforrenalcancer
AT johannsenmanfred braintypeandlivertypefattyacidbindingproteinsnewtumormarkersforrenalcancer
AT leinmichael braintypeandlivertypefattyacidbindingproteinsnewtumormarkersforrenalcancer
AT jungmonika braintypeandlivertypefattyacidbindingproteinsnewtumormarkersforrenalcancer
AT tolleangelika braintypeandlivertypefattyacidbindingproteinsnewtumormarkersforrenalcancer
AT jungklaus braintypeandlivertypefattyacidbindingproteinsnewtumormarkersforrenalcancer
AT kristiansenglen braintypeandlivertypefattyacidbindingproteinsnewtumormarkersforrenalcancer
_version_ 1724923534147321856